| 1 | The Dual Roles of Leucine-Rich Repeat-Containing Protein 15 Positive Fibroblasts: From Cancer to Tissue Repair | 1.8 | 6 | Citations (PDF) |
| 2 | Imaging mass cytometry-based characterisation of fibroblast subsets and their cellular niches in systemic sclerosis | 6.5 | 10 | Citations (PDF) |
| 3 | Combination therapies of porcupine inhibition with ruxolitinib, ibrutinib, or belumosudil in murine sclerodermatous GVHD | 3.7 | 2 | Citations (PDF) |
| 4 | Avenciguat: a novel soluble guanylate cyclase activator that affects multiple cell types to inhibit IFN-1 signalling and fibrosis | 1.4 | 6 | Citations (PDF) |
| 5 | Evaluation of Systemic Sclerosis Primary Heart Involvement and Chronic Heart Failure in the European Scleroderma Trials and Research Cohort | 3.1 | 25 | Citations (PDF) |
| 6 | Antifibrotic effects of specific targeting of the 5‐hydroxytryptamine 2B receptor (5‐HT2BR) in murine models and ex vivo models of scleroderma skin | 4.7 | 4 | Citations (PDF) |
| 7 | Fibrosis: cross-organ biology and pathways to development of innovative drugs | 42.5 | 90 | Citations (PDF) |
| 8 | Diffuse Hyperpigmentierung bei systemischer Sklerose | 0.3 | 0 | Citations (PDF) |
| 9 | Acidosis as a promising early indicator of mortality among point-of-care parameters and vital signs in non-traumatic critically ill patients | 1.7 | 4 | Citations (PDF) |
| 10 | Persisting CD19.CAR-T cells in combination with nintedanib: clinical response in a patient with systemic sclerosis-associated pulmonary fibrosis after 2 years | 15.9 | 13 | Citations (PDF) |
| 11 | Efficacy of obinutuzumab in two rituximab refractory cases of idiopathic inflammatory myopathies with severe interstitial lung disease | 6.5 | 2 | Citations (PDF) |
| 12 | Effect of Anti‐S100A4 Monoclonal Antibody Treatment on Experimental Skin Fibrosis and Systemic Sclerosis–Specific Transcriptional Signatures in Human Skin | 4.7 | 24 | Citations (PDF) |
| 13 | Fibroblast Subpopulations in Systemic Sclerosis: Functional Implications of Individual Subpopulations and Correlations with Clinical Features | 1.8 | 54 | Citations (PDF) |
| 14 | Population-based incidence of psoriasis vulgaris in Germany: analysis of national statutory insurance data from 65 million population | 0.9 | 3 | Citations (PDF) |
| 15 | Characterization of Vascular Niche in Systemic Sclerosis by Spatial Proteomics | 8.6 | 43 | Citations (PDF) |
| 16 | Attenuation of fibroblast activation and fibrosis by adropin in systemic sclerosis | 8.7 | 29 | Citations (PDF) |
| 17 | Combined inhibition of IL-1, IL-33 and IL-36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis | 6.5 | 34 | Citations (PDF) |
| 18 | Noncanonical WNT5A controls the activation of latent TGF-β to drive fibroblast activation and tissue fibrosis | 6.8 | 62 | Citations (PDF) |
| 19 | FAPI-PET/CT zur Quantifizierung der Gewebeantwort bei rheumatischen Erkrankungen | 0.7 | 3 | Citations (PDF) |
| 20 | Fibroblast activation protein inhibitor PET/CT as an emerging diagnostic modality in interstitial lung disease and other fibrotic conditions | 1.4 | 13 | Citations (PDF) |
| 21 | miR-3606-3p alleviates skin fibrosis by integratively suppressing the integrin/FAK, p-AKT/p-ERK, and TGF-β signaling cascades | 7.4 | 16 | Citations (PDF) |
| 22 | Identification of a Distinct Monocyte‐Driven Signature in Systemic Sclerosis Using Biophysical Phenotyping of Circulating Immune Cells | 4.7 | 10 | Citations (PDF) |
| 23 | The Exciting Future for Scleroderma | 0.9 | 6 | Citations (PDF) |
| 24 | Serum metabolomic profiling reveals potential biomarkers in systemic sclerosis | 9.0 | 35 | Citations (PDF) |
| 25 | Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells | 6.5 | 204 | Citations (PDF) |
| 26 | A population-based projection of psoriatic arthritis in Germany until 2050: analysis of national statutory health insurance data of 65 million German population | 1.8 | 10 | Citations (PDF) |
| 27 | Platelet Phagocytosis via P‐selectin Glycoprotein Ligand 1 and Accumulation of Microparticles in Systemic Sclerosis | 4.7 | 32 | Citations (PDF) |
| 28 | Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score | 4.7 | 31 | Citations (PDF) |
| 29 | Impaired Mitochondrial Transcription Factor A Expression Promotes Mitochondrial Damage to Drive Fibroblast Activation and Fibrosis in Systemic Sclerosis | 4.7 | 41 | Citations (PDF) |
| 30 | LDLR dysfunction induces LDL accumulation and promotes pulmonary fibrosis | 5.2 | 39 | Citations (PDF) |
| 31 | The role of antifibrotics in the treatment of rheumatoid arthritis–associated interstitial lung disease | 2.0 | 21 | Citations (PDF) |
| 32 | Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial | 4.7 | 115 | Citations (PDF) |
| 33 | Patient's Perception of Digital Symptom Assessment Technologies in Rheumatology: Results From a Multicentre Study | 1.9 | 40 | Citations (PDF) |
| 34 | Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment | 1.4 | 12 | Citations (PDF) |
| 35 | Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort | 1.4 | 42 | Citations (PDF) |
| 36 | Genetic Associations of Non–Major Histocompatibility Complex Susceptibility Loci with Systemic Sclerosis in a Han Chinese Population | 1.8 | 1 | Citations (PDF) |
| 37 | Deciphering Pro-angiogenic Transcription Factor Profiles in Hypoxic Human Endothelial Cells by Combined Bioinformatics and in vitro Modeling | 1.6 | 3 | Citations (PDF) |
| 38 | Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects | 2.8 | 8 | Citations (PDF) |
| 39 | Dynamic changes in O-GlcNAcylation regulate osteoclast differentiation and bone loss via nucleoporin 153 | 10.7 | 37 | Citations (PDF) |
| 40 | A broad look into the future of systemic sclerosis | 2.0 | 6 | Citations (PDF) |
| 41 | Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis | 2.9 | 28 | Citations (PDF) |
| 42 | Assessment of myocardial fibrosis in patients with systemic sclerosis using [68Ga]Ga-FAPI-04-PET-CT | 3.7 | 53 | Citations (PDF) |
| 43 | Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis | 6.5 | 16 | Citations (PDF) |
| 44 | Cellular and molecular mechanisms in fibrosis | 1.8 | 90 | Citations (PDF) |
| 45 | Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study | 2.7 | 10,518 | Citations (PDF) |
| 46 | Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial | 15.9 | 209 | Citations (PDF) |
| 47 | Targeting human plasmacytoid dendritic cells through BDCA2 prevents skin inflammation and fibrosis in a novel xenotransplant mouse model of scleroderma | 6.5 | 54 | Citations (PDF) |
| 48 | 68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study | 13.6 | 142 | Citations (PDF) |
| 49 | Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study | 13.6 | 32 | Citations (PDF) |
| 50 | X-linked inhibitor of apoptosis protein (XIAP) inhibition in systemic sclerosis (SSc) | 6.5 | 13 | Citations (PDF) |
| 51 | Cytokine-mediated induction of human xylosyltransferase-I in systemic sclerosis skin fibroblasts | 1.5 | 11 | Citations (PDF) |
| 52 | Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host diseaseBlood, 2021, 137, 2403-2416 | 3.6 | 22 | Citations (PDF) |
| 53 | Accuracy, patient-perceived usability, and acceptance of two symptom checkers (Ada and Rheport) in rheumatology: interim results from a randomized controlled crossover trial | 2.9 | 63 | Citations (PDF) |
| 54 | Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin | 2.5 | 7 | Citations (PDF) |
| 55 | Bone Morphogenetic Protein Antagonist Gremlin-1 Increases Myofibroblast Transition in Dermal Fibroblasts: Implications for Systemic Sclerosis | 2.8 | 16 | Citations (PDF) |
| 56 | An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod | 2.9 | 35 | Citations (PDF) |
| 57 | TGFβ promotes fibrosis by MYST1-dependent epigenetic regulation of autophagy | 11.0 | 103 | Citations (PDF) |
| 58 | Engrailed 1 coordinates cytoskeletal reorganization to induce myofibroblast differentiation | 5.9 | 48 | Citations (PDF) |
| 59 | Case report of severe constrictive perimyocarditis and ischemic hepatitis in a Crohn’s disease patient upon infliximab-induced lupus-like syndrome | 2.0 | 4 | Citations (PDF) |
| 60 | Purinergic signalling in systemic sclerosis | 1.4 | 1 | Citations (PDF) |
| 61 | The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease | 3.1 | 4 | Citations (PDF) |
| 62 | Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis | 4.7 | 117 | Citations (PDF) |
| 63 | Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study | 1.4 | 71 | Citations (PDF) |
| 64 | Fibroblast growth factor receptor 3 activates a network of profibrotic signaling pathways to promote fibrosis in systemic sclerosis | 8.7 | 43 | Citations (PDF) |
| 65 | Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging | 6.5 | 177 | Citations (PDF) |
| 66 | cRel expression regulates distinct transcriptional and functional profiles driving fibroblast matrix production in systemic sclerosis | 1.4 | 9 | Citations (PDF) |
| 67 | PGC-1α regulates autophagy to promote fibroblast activation and tissue fibrosis | 6.5 | 39 | Citations (PDF) |
| 68 | Recombinant Adenosine Deaminase Ameliorates Inflammation, Vascular Disease, and Fibrosis in Preclinical Models of Systemic Sclerosis | 4.7 | 21 | Citations (PDF) |
| 69 | Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs | 1.5 | 39 | Citations (PDF) |
| 70 | The α7 Nicotinic Acetylcholine Receptor: A Promising Target for the Treatment of Fibrotic Skin Disorders | 1.8 | 11 | Citations (PDF) |
| 71 | Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse | 4.8 | 31 | Citations (PDF) |
| 72 | Predictors of progression in systemic sclerosis patients with interstitial lung disease | 6.5 | 229 | Citations (PDF) |
| 73 | microRNA-145 mediates xylosyltransferase-I induction in myofibroblasts via suppression of transcription factor KLF4 | 1.5 | 12 | Citations (PDF) |
| 74 | Therapeutic molecular targets of SSc-ILD | 0.6 | 11 | Citations (PDF) |
| 75 | TGF-β–induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis | 6.8 | 141 | Citations (PDF) |
| 76 | Long noncoding RNA H19X is a key mediator of TGF-β–driven fibrosis | 6.8 | 78 | Citations (PDF) |
| 77 | Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases | 1.3 | 52 | Citations (PDF) |
| 78 | Imatinib-loaded gold nanoparticles inhibit proliferation of fibroblasts and macrophages from systemic sclerosis patients and ameliorate experimental bleomycin-induced lung fibrosis | 8.3 | 59 | Citations (PDF) |
| 79 | Regulation of Fibroblast Apoptosis and Proliferation by MicroRNA‐125b in Systemic Sclerosis | 4.7 | 22 | Citations (PDF) |
| 80 | Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases | 6.5 | 260 | Citations (PDF) |
| 81 | GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways | 11.0 | 189 | Citations (PDF) |
| 82 | Shared and distinct mechanisms of fibrosis | 17.1 | 612 | Citations (PDF) |
| 83 | PU.1 controls fibroblast polarization and tissue fibrosis | 31.3 | 189 | Citations (PDF) |
| 84 | Notch Signaling Activity Determines Uptake and Biological Effect of Imatinib in Systemic Sclerosis Dermal Fibroblasts | 1.8 | 19 | Citations (PDF) |
| 85 | Acyltransferase skinny hedgehog regulates TGFβ-dependent fibroblast activation in SSc | 6.5 | 23 | Citations (PDF) |
| 86 | Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study | 6.5 | 177 | Citations (PDF) |
| 87 | Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual | 6.5 | 27 | Citations (PDF) |
| 88 | Vascularised human skin equivalents as a novel in vitro model of skin fibrosis and platform for testing of antifibrotic drugs | 6.5 | 49 | Citations (PDF) |
| 89 | Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course | 1.8 | 189 | Citations (PDF) |
| 90 | Targeting TGF-β signaling for the treatment of fibrosis | 3.5 | 270 | Citations (PDF) |
| 91 | Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis | 6.5 | 44 | Citations (PDF) |
| 92 | Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators | 6.5 | 45 | Citations (PDF) |
| 93 | Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study | 6.5 | 71 | Citations (PDF) |
| 94 | Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study | 1.4 | 72 | Citations (PDF) |
| 95 | Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis | 6.5 | 17 | Citations (PDF) |
| 96 | The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis | 6.5 | 63 | Citations (PDF) |
| 97 | Innate lymphoid cells and fibrotic regulation | 1.7 | 17 | Citations (PDF) |
| 98 | NR4A1 Regulates Motility of Osteoclast Precursors and Serves as Target for the Modulation of Systemic Bone Turnover | 3.3 | 24 | Citations (PDF) |
| 99 | Autoantibodies Recognizing Secondary NEcrotic Cells Promote Neutrophilic Phagocytosis and Identify Patients With Systemic Lupus Erythematosus | 3.3 | 12 | Citations (PDF) |
| 100 | The tyrosine phosphatase SHP2 controls TGFβ-induced STAT3 signaling to regulate fibroblast activation and fibrosis | 11.0 | 122 | Citations (PDF) |
| 101 | Pharmacological inhibition of porcupine induces regression of experimental skin fibrosis by targeting Wnt signalling | 6.5 | 33 | Citations (PDF) |
| 102 | Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages | 6.5 | 95 | Citations (PDF) |
| 103 | The transcription factor GLI2 as a downstream mediator of transforming growth factor-β-induced fibroblast activation in SSc | 6.5 | 70 | Citations (PDF) |
| 104 | Composition of TWIST1 dimers regulates fibroblast activation and tissue fibrosis | 6.5 | 47 | Citations (PDF) |
| 105 | Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS) | 6.5 | 135 | Citations (PDF) |
| 106 | JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment | 6.5 | 52 | Citations (PDF) |
| 107 | Epigenetic Factors as Drivers of Fibrosis in Systemic Sclerosis | 1.6 | 40 | Citations (PDF) |
| 108 | Update of EULAR recommendations for the treatment of systemic sclerosis | 6.5 | 997 | Citations (PDF) |
| 109 | Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis | 11.0 | 343 | Citations (PDF) |
| 110 | Mapping and predicting mortality from systemic sclerosis | 6.5 | 659 | Citations (PDF) |
| 111 | Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis | 6.5 | 187 | Citations (PDF) |
| 112 | Tie2 as a novel key factor of microangiopathy in systemic sclerosis | 2.9 | 34 | Citations (PDF) |
| 113 | Targeting of NADPH oxidase in vitro and in vivo suppresses fibroblast activation and experimental skin fibrosis | 1.8 | 34 | Citations (PDF) |
| 114 | Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis | 4.7 | 74 | Citations (PDF) |
| 115 | Sirt1 regulates canonical TGF-β signalling to control fibroblast activation and tissue fibrosis | 6.5 | 143 | Citations (PDF) |
| 116 | Effect of endothelin-1 receptor antagonists on skin fibrosis in scleroderma patients from the EUSTAR database | 0.6 | 5 | Citations (PDF) |
| 117 | Emerging strategies for treatment of systemic sclerosis | 0.6 | 42 | Citations (PDF) |
| 118 | Updates on animal models of systemic sclerosis | 0.6 | 16 | Citations (PDF) |
| 119 | Inhibition of Notch1 promotes hedgehog signalling in a HES1-dependent manner in chondrocytes and exacerbates experimental osteoarthritis | 6.5 | 44 | Citations (PDF) |
| 120 | Evidence of innate lymphoid cell redundancy in humans | 14.4 | 296 | Citations (PDF) |
| 121 | Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross‐Disease Meta‐Analysis of Genome‐Wide Association Studies | 4.7 | 55 | Citations (PDF) |
| 122 | Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression | 6.5 | 50 | Citations (PDF) |
| 123 | Tribbles homologue 3 stimulates canonical TGF-β signalling to regulate fibroblast activation and tissue fibrosis | 6.5 | 47 | Citations (PDF) |
| 124 | Canonical Wnt signaling in systemic sclerosis | 1.9 | 70 | Citations (PDF) |
| 125 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) | 11.9 | 5,055 | Citations (PDF) |
| 126 | Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway | 6.5 | 59 | Citations (PDF) |
| 127 | Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database | 6.5 | 80 | Citations (PDF) |
| 128 | Activating transcription factor 3 regulates canonical TGFβ signalling in systemic sclerosis | 6.5 | 34 | Citations (PDF) |
| 129 | Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis | 6.5 | 90 | Citations (PDF) |
| 130 | Inactivation of autophagy ameliorates glucocorticoid-induced and ovariectomy-induced bone loss | 6.5 | 117 | Citations (PDF) |
| 131 | Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis | 6.5 | 184 | Citations (PDF) |
| 132 | Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study | 1.5 | 226 | Citations (PDF) |
| 133 | Inhibition of casein kinase II reduces TGFβ induced fibroblast activation and ameliorates experimental fibrosis | 6.5 | 62 | Citations (PDF) |
| 134 | Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling | 6.5 | 119 | Citations (PDF) |
| 135 | Orphan nuclear receptor NR4A1 regulates transforming growth factor-β signaling and fibrosis | 22.8 | 343 | Citations (PDF) |
| 136 | Implication of bisphosphonate use in the treatment of SAPHO syndrome: Case report and discussion of current literature | 0.6 | 11 | Citations (PDF) |
| 137 | From pathogenesis to therapy – Perspective on treatment strategies in fibrotic diseases | 6.5 | 18 | Citations (PDF) |
| 138 | Cardiomyopathy in Murine Models of Systemic Sclerosis | 4.7 | 45 | Citations (PDF) |
| 139 | Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies | 6.5 | 68 | Citations (PDF) |
| 140 | Systemische Sklerose – ein Update | 0.1 | 0 | Citations (PDF) |
| 141 | Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis | 2.0 | 24 | Citations (PDF) |
| 142 | Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages | 6.5 | 32 | Citations (PDF) |
| 143 | Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group | 6.5 | 392 | Citations (PDF) |
| 144 | S100A4 amplifies TGF-β-induced fibroblast activation in systemic sclerosis | 6.5 | 72 | Citations (PDF) |
| 145 | Vitamin D receptor regulates TGF-β signalling in systemic sclerosis | 6.5 | 139 | Citations (PDF) |
| 146 | Anti‐Fibrotic Effect of Ajulemic Acid in Bleomycin‐Induced Lung Fibrosis | 2.3 | 0 | Citations (PDF) |
| 147 | Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis | 6.5 | 87 | Citations (PDF) |
| 148 | The Nuclear Receptor Constitutive Androstane Receptor/NR1I3 Enhances the Profibrotic Effects of Transforming Growth Factor β and Contributes to the Development of Experimental Dermal Fibrosis | 4.7 | 15 | Citations (PDF) |
| 149 | Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability | 6.5 | 36 | Citations (PDF) |
| 150 | The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis | 6.5 | 189 | Citations (PDF) |
| 151 | Inactivation of evenness interrupted (EVI) reduces experimental fibrosis by combined inhibition of canonical and non-canonical Wnt signalling | 6.5 | 28 | Citations (PDF) |
| 152 | Immunochip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis | 4.5 | 210 | Citations (PDF) |
| 153 | Treating skin and lung fibrosis in systemic sclerosis: a future filled with promise? | 2.9 | 17 | Citations (PDF) |
| 154 | Activation of pregnane X receptor inhibits experimental dermal fibrosis | 6.5 | 25 | Citations (PDF) |
| 155 | The Fra-2 transgenic mouse model of systemic sclerosis | 1.2 | 64 | Citations (PDF) |
| 156 | Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis | 6.5 | 106 | Citations (PDF) |
| 157 | Tyrosine kinase signaling in fibrotic disorders | 2.8 | 113 | Citations (PDF) |
| 158 | Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling | 6.5 | 83 | Citations (PDF) |
| 159 | Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis | 6.5 | 113 | Citations (PDF) |
| 160 | Canonical Wnt signalling as a key regulator of fibrogenesis – implications for targeted therapies? | 1.8 | 59 | Citations (PDF) |
| 161 | Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors | 6.5 | 20 | Citations (PDF) |
| 162 | New insight on the Xq28 association with systemic sclerosis | 6.5 | 58 | Citations (PDF) |
| 163 | Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis | 6.5 | 40 | Citations (PDF) |
| 164 | Mitogen-activated protein kinase 2 regulates physiological and pathological bone turnover | 3.3 | 12 | Citations (PDF) |
| 165 | The Systemic Lupus Erythematosus IRF5 Risk Haplotype Is Associated with Systemic Sclerosis | 1.5 | 39 | Citations (PDF) |
| 166 | The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis | 6.5 | 40 | Citations (PDF) |
| 167 | A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations | 2.1 | 79 | Citations (PDF) |
| 168 | Innovative antifibrotic therapies in systemic sclerosis | 2.5 | 49 | Citations (PDF) |
| 169 | Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis | 6.5 | 96 | Citations (PDF) |
| 170 | Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis | 6.5 | 61 | Citations (PDF) |
| 171 | Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis | 6.5 | 79 | Citations (PDF) |
| 172 | Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis | 6.5 | 80 | Citations (PDF) |
| 173 | Pomalidomide is effective for prevention and treatment of experimental skin fibrosis | 6.5 | 35 | Citations (PDF) |
| 174 | Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1 | 6.5 | 29 | Citations (PDF) |
| 175 | Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up | 2.1 | 106 | Citations (PDF) |
| 176 | Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host diseaseBlood, 2012, 120, 2909-2917 | 3.6 | 62 | Citations (PDF) |
| 177 | Inhibition of sumoylation prevents experimental fibrosis | 6.5 | 32 | Citations (PDF) |
| 178 | Influence of the IL6 Gene in Susceptibility to Systemic Sclerosis | 1.2 | 35 | Citations (PDF) |
| 179 | Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis | 6.5 | 106 | Citations (PDF) |
| 180 | The extracellular release of DNA and HMGB1 from Jurkat T cells during
in vitro
necrotic cell death | 2.3 | 64 | Citations (PDF) |
| 181 | JAK‐2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis | 6.4 | 144 | Citations (PDF) |
| 182 | Combined Inhibition of c-Abl and PDGF Receptors for Prevention and Treatment of Murine Sclerodermatous Chronic Graft-versus-Host Disease | 2.8 | 31 | Citations (PDF) |
| 183 | Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis | 11.0 | 802 | Citations (PDF) |
| 184 | Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis | 2.9 | 11 | Citations (PDF) |
| 185 | WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production | 3.3 | 111 | Citations (PDF) |
| 186 | Inhibition of activator protein 1 signaling abrogates transforming growth factor β–mediated activation of fibroblasts and prevents experimental fibrosis | 6.4 | 95 | Citations (PDF) |
| 187 | Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis | 6.4 | 154 | Citations (PDF) |
| 188 | β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis | 6.5 | 198 | Citations (PDF) |
| 189 | Morphogen pathways as molecular targets for the treatment of fibrosis in systemic sclerosis | 0.9 | 30 | Citations (PDF) |
| 190 | Morphogen Pathways in Systemic Sclerosis | 2.7 | 28 | Citations (PDF) |
| 191 | Inhibition of glycogen synthase kinase 3β induces dermal fibrosis by activation of the canonical Wnt pathway | 6.5 | 102 | Citations (PDF) |
| 192 | Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis | 6.5 | 148 | Citations (PDF) |
| 193 | Epigenetic modifications: novel therapeutic strategies for systemic sclerosis? | 2.3 | 27 | Citations (PDF) |
| 194 | Microparticles stimulate angiogenesis by inducing ELR+ CXC-chemokines in synovial fibroblasts | 2.4 | 50 | Citations (PDF) |
| 195 | Prevalence of paraneoplastic rheumatic syndromes and their antibody profile among patients with solid tumours | 1.3 | 18 | Citations (PDF) |
| 196 | Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis | 6.4 | 84 | Citations (PDF) |
| 197 | Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis | 6.4 | 121 | Citations (PDF) |
| 198 | Induction of apoptosis in circulating angiogenic cells by microparticles | 6.4 | 38 | Citations (PDF) |
| 199 | The transcription factor JunD mediates transforming growth factor β-induced fibroblast activation and fibrosis in systemic sclerosis | 6.5 | 65 | Citations (PDF) |
| 200 | Platelet-derived serotonin links vascular disease and tissue fibrosis | 5.9 | 251 | Citations (PDF) |
| 201 | Genome-Wide Scan Identifies TNIP1, PSORS1C1, and RHOB as Novel Risk Loci for Systemic Sclerosis | 2.2 | 227 | Citations (PDF) |
| 202 | Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease | 6.5 | 24 | Citations (PDF) |
| 203 | The transcription factor Fra‐2 regulates the production of extracellular matrix in systemic sclerosis | 6.4 | 109 | Citations (PDF) |
| 204 | Decreased lymphatic vessel counts in patients with systemic sclerosis: Association with fingertip ulcers | 6.4 | 25 | Citations (PDF) |
| 205 | MicroRNA‐29, a key regulator of collagen expression in systemic sclerosis | 6.4 | 506 | Citations (PDF) |
| 206 | Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis | 6.4 | 74 | Citations (PDF) |
| 207 | Animal models of systemic sclerosis: Prospects and limitations | 6.4 | 145 | Citations (PDF) |
| 208 | Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: From Animal Models to Clinical Trials | 2.7 | 41 | Citations (PDF) |
| 209 | Transcription Factor Fos-Related Antigen-2 Induces Progressive Peripheral Vasculopathy in Mice Closely Resembling Human Systemic Sclerosis | 13.1 | 113 | Citations (PDF) |
| 210 | Lack of inhibitory effects of the anti‐fibrotic drug imatinib on endothelial cell functions in vitro and in vivo | 2.4 | 12 | Citations (PDF) |
| 211 | Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis | 6.4 | 198 | Citations (PDF) |
| 212 | The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis | 6.4 | 120 | Citations (PDF) |
| 213 | Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis | 6.4 | 111 | Citations (PDF) |
| 214 | Endothelial progenitor cells: Novel players in the pathogenesis of rheumatic diseases | 6.4 | 41 | Citations (PDF) |
| 215 | Inhibitor of DNA binding/differentiation 2 induced by hypoxia promotes synovial fibroblast–dependent osteoclastogenesis | 6.4 | 15 | Citations (PDF) |
| 216 | Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis | 2.9 | 120 | Citations (PDF) |
| 217 | The scientific basis for novel treatments of systemic sclerosis | 1.0 | 3 | Citations (PDF) |
| 218 | Src kinases in systemic sclerosis: Central roles in fibroblast activation and in skin fibrosis | 6.4 | 117 | Citations (PDF) |
| 219 | The controversial role of tumor necrosis factor α in fibrotic diseases | 6.4 | 104 | Citations (PDF) |
| 220 | Rho‐associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts | 6.4 | 112 | Citations (PDF) |
| 221 | Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease | 6.4 | 43 | Citations (PDF) |
| 222 | The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis | 6.4 | 100 | Citations (PDF) |
| 223 | Novel Treatment Approaches to Fibrosis in Scleroderma | 0.9 | 16 | Citations (PDF) |
| 224 | Dual inhibition of c‐abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis | 2.3 | 186 | Citations (PDF) |
| 225 | Imatinib as a novel therapeutic approach for fibrotic disorders | 1.4 | 31 | Citations (PDF) |
| 226 | Criteria to select molecular targets for anti-fibrotic therapy | 1.4 | 14 | Citations (PDF) |
| 227 | Diagnosis of pulmonary arterial hypertension in a patient with systemic sclerosis | 4.3 | 2 | Citations (PDF) |
| 228 | Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect? | 6.5 | 21 | Citations (PDF) |
| 229 | Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis | 6.4 | 370 | Citations (PDF) |
| 230 | Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin‐induced skin fibrosis | 6.4 | 165 | Citations (PDF) |
| 231 | Microparticles stimulate the synthesis of prostaglandin E2 via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1 | 6.4 | 87 | Citations (PDF) |
| 232 | Hypoxia‐induced increase in the production of extracellular matrix proteins in systemic sclerosis | 6.4 | 184 | Citations (PDF) |
| 233 | Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells | 6.4 | 91 | Citations (PDF) |
| 234 | Microparticles as mediators of cellular cross-talk in inflammatory disease | 2.5 | 160 | Citations (PDF) |
| 235 | Nucleofection: a new, highly efficient transfection method for primary human keratinocytes* | 1.8 | 53 | Citations (PDF) |
| 236 | Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis | 6.4 | 133 | Citations (PDF) |
| 237 | Microparticles as regulators of inflammation: Novel players of cellular crosstalk in the rheumatic diseases | 6.4 | 221 | Citations (PDF) |
| 238 | The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles | 5.3 | 387 | Citations (PDF) |
| 239 | The release of microparticles by apoptotic cells and their effects on macrophages | 4.8 | 139 | Citations (PDF) |
| 240 | Bucillamine Induces the Synthesis of Vascular Endothelial Growth Factor Dose-Dependently in Systemic Sclerosis Fibroblasts via Nuclear Factor-κB and Simian Virus 40 Promoter Factor 1 Pathways | 2.4 | 23 | Citations (PDF) |
| 241 | Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis | 6.4 | 103 | Citations (PDF) |
| 242 | Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis | 6.4 | 162 | Citations (PDF) |
| 243 | Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis | 8.6 | 293 | Citations (PDF) |
| 244 | Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease | 1.4 | 18 | Citations (PDF) |
| 245 | Emerging therapies for the treatment of systemic sclerosis | 17.1 | 18 | Citations (PDF) |
| 246 | Mosunetuzumab, a CD20xCD3 bispecific T-cell engager, in granulomatosis with polyangiitis | 6.5 | 3 | Citations (PDF) |
| 247 | Guidance for the management of SARD-ILDs in clinical practice—impact of the ERS/EULAR recommendations | 6.5 | 1 | Citations (PDF) |
| 248 | Mechanisms of fibrotic tissue remodelling: insights from systemic sclerosis | 17.1 | 12 | Citations (PDF) |
| 249 | High Rates of Degenerative Changes in the Lower Spine in Calcium Pyrophosphate Deposition Disease Compared to Degenerative Disc Disease | 1.2 | 0 | Citations (PDF) |
| 250 | Low-energy small language models with retrieval-augmented generation can surpass large-model performance in rheumatology | 1.7 | 1 | Citations (PDF) |
| 251 | A first‐in‐human study of CAL101, a monoclonal antibody targeting S100A4 | 1.5 | 0 | Citations (PDF) |
